NHS Framework Agreement-Branded Medicines - National Proprietary Pharmaceuticals

NHS EnglandcontractContracts Finder ↗Ref CF-1454500D0O000000rwimUAASME suitablecomplete

Estimated value

£304.5m

Awarded value

£304.5m

Awarded 23 Apr 2023

Suppliers

1

Lots

1

1 awarded

Published

06 Apr 2023

Deadline 12 Dec 2022

Awarded suppliers· 1 supplier

Awarded 23 Apr 2023 · Contract period 30 Apr 2023 — 29 Apr 2025

Award value

£304.5m

1

MP

Mercury Pharmaceuticals Limited,Gerot Lannach UK Ltd,Bayer Plc,Aventis Pharma ltd t/a Sanofi,Tillomed Laboratories ltd,Sandoz Ltd,Pfizer Ltd,Accord-UK Ltd,Otsuka Pharmaceuticals UK Limited,Morningside Pharmaeuticals,Astellas Pharma Ltd,Wockhardt UK Limited,Lupin Healthcare (UK) Limited,Ipsen,Mylan,Neuraxpharm UK Ltd,Ridge Pharma,Ferring Pharmaceuticals Ltd,Drugsrus Ltd,medac Pharma LLP,Kent Pharma Ltd,Martindale Pharma,Janssen-Cilag Ltd,Day Lewis Medical Ltd,Zentiva Pharma UK Ltd,Teva UK Limited,Glenmark Pharmaceuticals Europe Limited,Pharmasure,Xiromed,Recordati Rare Diseases UK Ltd,Aspire Pharma Limited,Chiesi Limited,Selective Supplies Ltd.,Napp Pharmaceuticals Ltd,Aspen Pharmacare UK Limited,Gedeon Richter UK Ltd,Nordic Pharma,Novartis Pharmaceuticals UK Ltd,Synchrony,Norgine Pharmaceuticals Limited,Orifarm UK,QDEM PHARMACEUTICALS LIMITED,Eli Lilly & Company Ltd,CST Pharma Limited,ROVI Biotech Ltd,Merck Serono Limited,Takeda UK Ltd,Tetris Pharma Lts,Dexcel Pharma Ltd,Theramex HQ UK